Guardian Pharmacy Services (NYSE:GRDN) Stock Price Down 5.5% – Time to Sell?

Guardian Pharmacy Services, Inc. (NYSE:GRDN)’s stock price dropped 5.5% on Tuesday . The stock traded as low as $39.54 and last traded at $39.1860. Approximately 121,588 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 388,726 shares. The stock had previously closed at $41.47.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GRDN. Oppenheimer boosted their price target on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a research note on Friday. Bank of America raised their price objective on shares of Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Wall Street Zen raised Guardian Pharmacy Services from a “hold” rating to a “buy” rating in a report on Sunday. Weiss Ratings upgraded Guardian Pharmacy Services from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday. Finally, Truist Financial increased their target price on Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Guardian Pharmacy Services has a consensus rating of “Moderate Buy” and an average price target of $43.83.

Guardian Pharmacy Services Stock Down 4.3%

The stock’s fifty day simple moving average is $40.96 and its 200-day simple moving average is $37.25. The company has a market capitalization of $1.98 billion, a PE ratio of 38.55, a PEG ratio of 2.87 and a beta of 0.11.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.26 by $0.03. The business had revenue of $351.77 million for the quarter, compared to analyst estimates of $340.45 million. Guardian Pharmacy Services had a return on equity of 29.97% and a net margin of 4.50%. Analysts expect that Guardian Pharmacy Services, Inc. will post 1.18 EPS for the current year.

Institutional Trading of Guardian Pharmacy Services

Several large investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. raised its stake in shares of Guardian Pharmacy Services by 26.5% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock worth $43,000 after buying an additional 345 shares during the last quarter. California State Teachers Retirement System grew its stake in Guardian Pharmacy Services by 3.4% in the 4th quarter. California State Teachers Retirement System now owns 17,983 shares of the company’s stock valued at $541,000 after acquiring an additional 593 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in Guardian Pharmacy Services by 20.4% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 6,070 shares of the company’s stock valued at $183,000 after acquiring an additional 1,028 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Guardian Pharmacy Services by 13.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,885 shares of the company’s stock valued at $358,000 after acquiring an additional 1,409 shares during the last quarter. Finally, Clearstead Advisors LLC increased its holdings in Guardian Pharmacy Services by 196.3% during the 4th quarter. Clearstead Advisors LLC now owns 2,628 shares of the company’s stock valued at $79,000 after acquiring an additional 1,741 shares in the last quarter.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.